Maternal mortality Clinical assessment · women with postpartum iron deficiency anaemia
Intravenous iron showed no clear difference in maternal mortality Clinical assessment compared with oral iron (low certainty).
1 finding from 1 review
Fatigue · women with postpartum iron deficiency anaemia
1 finding from 1 review
Persistent anaemia symptoms ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infections Clinical assessment · women with postpartum iron deficiency anaemia
It is very uncertain whether intravenous iron changes infections Clinical assessment compared with oral iron (very low certainty).
1 finding from 1 review
Constipation · women with postpartum iron deficiency anaemia
It is very uncertain whether intravenous iron changes constipation Reported by the women compared with oral iron (very low certainty).
1 finding from 1 review
All gastrointestinal symptoms Reported by the women · women with postpartum iron deficiency anaemia
It is very uncertain whether intravenous iron changes all gastrointestinal symptoms Reported by the women compared with oral iron (very low certainty).
1 finding from 1 review
Anaphylaxis or evidence of hypersensitivity Clinical assessment · women with postpartum iron deficiency anaemia
Intravenous iron showed no clear difference in anaphylaxis or evidence of hypersensitivity Clinical assessment compared with oral iron (low certainty).
1 finding from 1 review
Material deficiency (retention/adaptation loss; re-treatment) · Dentate children and adults with non-cavitated proximal caries lesions extending into enamel or dentine (not pulp) in primary or permanent…
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes leaving the study early ‐ short term Rate of attrition compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review